| Literature DB >> 27871062 |
Daan R van der Veen1, Menno P Gerkema2.
Abstract
Biological oscillations with an ultradian time scale of 1 to several hours include cycles in behavioral arousal, episodic glucocorticoid release, and gene expression. Ultradian rhythms are thought to have an extrinsic origin because of a perceived absence of ultradian rhythmicity in vitro and a lack of known molecular ultradian oscillators. We designed a novel, non-spectral-analysis method of separating ultradian from circadian components and applied it to a published gene expression dataset with an ultradian sampling resolution. Ultradian rhythms in mouse hepatocytes in vivo have been published, and we validated our approach using this control by confirming 175 of 323 ultradian genes identified in a prior study and found 862 additional ultradian genes. For the first time, we now report ultradian expression of >900 genes in vitro Sixty genes exhibited ultradian transcriptional rhythmicity, both in vivo and in vitro, including 5 genes involved in the cell cycle. Within these 60 genes, we identified significant enrichment of specific DNA motifs in the 1000 bp proximal promotor, some of which associate with known transcriptional factors. These findings are in strong support of instrinsically driven ultradian rhythms and expose potential molecular mechanisms and functions underlying ultradian rhythms that remain unknown.-Van der Veen, D. R., Gerkema, M. P. Unmasking ultradian rhythms in gene expression.Entities:
Keywords: biological rhythm; cell culture; circadian; metabolism; transcriptome
Mesh:
Substances:
Year: 2016 PMID: 27871062 PMCID: PMC5240665 DOI: 10.1096/fj.201600872R
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191
Figure 1.Method of detection of ultradian rhythms in gene expression, with the 48-h expression profile of Prrc1 used as an example. A, B) An expression pattern is considered potentially ultradian when both the first and second half of the data (A) exhibit similar periodicity in an autocorrelation analysis (B). C, D) The second criterion, that an ultradian rhythm is not an artifact of a low-frequency fundamental signal, is tested by applying a low-pass filter (C), and retesting for ultradian periods using autocorrelation analysis (D). E) Finally, the ultradian waveform must consistently be expressed throughout the dataset, as evidenced by observing a value of R2 ≥ 0.6 in the regression of the average ultradian waveform against the actual signal.
Figure 2.Three examples of probes detected as ultradian by our method. Top: the solid lines show the original expression data obtained from Hughes et al. (14), which were not identified as ultradian in their publication. Green line: the low-frequency signal that was removed in our method. Bottom: the achieved residual ultradian signal (plotted in black) and the average ± se ultradian waveform (plotted in red). All 3 probes passed all criteria for ultradian gene expression.
Figure 3.A) Examples of ultradian residuals (black) and average ultradian waveform (red) for 3 probes classified as exhibiting ultradian expression patterns in NIH-3T3 cells in vitro. B) Comparison of the period distributions of ultradian rhythms in vivo and in vitro demonstrates that the largest group of in vitro ultradian rhythms oscillate with a period close to 8–9 h, whereas the largest group of ultradian rhythms in vivo exhibit a period close to 12–13 h. C) The difference in the period distribution between in vivo and in vitro ultradian rhythms is also reflected by the clustering of ultradian peak phases, which exhibit more clusters in vitro than in vivo.
Top 10 Gene Ontology terms for ultradian genes in both the liver in vivo and NIH-3T3 cells in vitro
| Process | Gene (%) | |
|---|---|---|
| Organic substance metabolic process | 41.90 | 0.0364 |
| Primary metabolic process | 40.53 | 0.0316 |
| Cellular metabolic process | 40.21 | 0.0316 |
| Macromolecule metabolic process | 35.03 | 0.016 |
| Cellular macromolecule metabolic process | 32.28 | 0.0088 |
| Intracellular transport | 6.56 | 0.0316 |
| Protein catabolic process | 4.13 | 0.0316 |
| Proteolysis involved in cellular protein catabolic process | 3.07 | 0.0588 |
| Ubiquitin-dependent protein catabolic process | 2.86 | 0.0588 |
| Intrinsic apoptotic signaling pathway | 1.38 | 0.0588 |
| Metabolic process | 43.60 | 5.07E-05 |
| Single-organism metabolic process | 40.74 | 0.0002 |
| Organic substance metabolic process | 39.05 | 0.0006 |
| Cellular metabolic process | 38.52 | 4.98E-05 |
| Primary metabolic process | 37.88 | 0.0003 |
| Macromolecule metabolic process | 32.49 | 0.0002 |
| Cellular macromolecule metabolic process | 30.26 | 5.07E-05 |
| Nucleic acid metabolic process | 20.21 | 0.0006 |
| Chromosome organization | 5.40 | 0.0002 |
| Protein modification by small protein conjugation or removal | 4.13 | 0.0006 |
Significant KEGG pathways for genes that exhibit ultradian mRNA expression profiles in both in vivo and in vitro conditions
| KEGG pathway | |
|---|---|
| Cell cycle | 0.0318 |
| Base excision repair | 0.0318 |
| Non–small-cell lung cancer | 0.0426 |
| Glioma | 0.0426 |
| Chronic myeloid leukemia | 0.0442 |
| ErbB signaling pathway | 0.0482 |
| Prostate cancer | 0.0482 |
Figure 4.MEME analysis of the 1000-bp proximal promotor of the 60 genes that exhibit ultradian mRNA expression profiles in both in vivo and in vitro conditions.